Foghorn Therapeutics Stock (NASDAQ: FHTX)

Foghorn Therapeutics

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Sankt-petersburg,,Russia,,February,8,,2018:,Paypal,Application,Icon,On,Apple

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

FHTX

OKLO

PYPL

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday

pvh_calvin_klein_shutterstock_753006271

Movers

BIAF

CMBM

CSAI

DIBS

LGCL

MVST

MYGN

NMAX

NUTX

ONTF

PRGS

RSLS

SLNH

TNMG

ZBIO

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

May,30,,2024,,Brazil.,In,This,Photo,Illustration,,The,Worthington

KSCP

PHIN

SRZN

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Foghorn Therapeutics Inc

Commodities

Press Releases

Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Contracts

Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

Management

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

MRNA

SANA

Abeona Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Astria Therapeutics

Candel Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

ITeos Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

AVITA Medical

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Acelyrin

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

JMP Securities

HC Wainwright & Co.

B. Riley Securities

Jefferies

Comments

Foghorn Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell